| Symbol | INM |
|---|---|
| Name | INMED PHARMACEUTICALS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | SUITE 1445 ¿ 885 WEST GEORGIA STREET, VANCOUVER, British Columbia, V6C 3E8, Canada |
| Telephone | +1 604 669-7207 |
| Fax | — |
| — | |
| Website | https://www.inmedpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001728328 |
| Description | InMed Pharmaceuticals Inc is a Canada based pre-clinical stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based therapies combined with drug delivery systems. It is focused on the treatment of diseases including pain and inflammation, dermatology, Orofacial Pain, Glaucoma, ocular, CNS, respiratory, metabolic diseases, and others. Additional info from NASDAQ: |
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Read more(99% Neutral) INMED PHARMACEUTICALS INC. (INM) Announces Regulatory Update
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more(99% Neutral) INMED PHARMACEUTICALS INC. (INM) Announces Update on Collaboration with B.C. Canada
Read moreNew Form 424B5 - InMed Pharmaceuticals Inc. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001213900-26-039938 <b>Size:</b> 359 KB
Read moreNew Form EFFECT - InMed Pharmaceuticals Inc. <b>Filed:</b> 2026-03-30 <b>AccNo:</b> 9999999995-26-000999 <b>Size:</b> 1 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04908215 | INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa | Phase2 | Epidermolysis Bullosa Simplex | Completed | 2021-12-28 | 2023-04-19 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vehicle Cream | Other | Phase PHASE2 | Epidermolysis Bullosa Simplex | COMPLETED | NCT04908215 |
| INM-755 (cannabinol) cream | Other | Phase PHASE2 | Epidermolysis Bullosa Simplex | COMPLETED | NCT04908215 |
| KDT501 | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02444910 |
| Vehicle Cream | DRUG | Phase PHASE2 | Epidermolysis Bullosa Simplex | COMPLETED | NCT04908215 |
| INM-755 (cannabinol) cream | DRUG | Phase PHASE2 | Epidermolysis Bullosa Simplex | COMPLETED | NCT04908215 |